Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants

NCT02792192 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
24
Enrollment
INDUSTRY
Sponsor class

Stopped The study was terminated early as the study had met its goals of providing preliminary safety and efficacy information for atezolizumab monotherapy alone and in combination with BCG in NMIBC.

Conditions

Interventions

Sponsor

Hoffmann-La Roche